Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres
| Autor: | Matthew Harries, Rosalyn Fox, Zena Salih, Anne C Armstrong, Helen Wong, Donna Arundell, Manal Alameddine, Helen Adderley, Christine Tetlow, Joachim Chan, Nicola Thorp, Jonathan Lim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Breast Neoplasms 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Internal medicine Surveys and Questionnaires Antineoplastic Combined Chemotherapy Protocols medicine Humans Retrospective Studies Chemotherapy Taxane business.industry Cancer Alopecia medicine.disease United Kingdom Hair loss Paclitaxel chemistry Docetaxel 030220 oncology & carcinogenesis Quality of Life Female Taxoids business Tamoxifen medicine.drug |
| Zdroj: | European journal of cancer careREFERENCES. 30(3) |
| ISSN: | 1365-2354 |
| Popis: | PURPOSE Taxane chemotherapy is commonly used in the management of breast cancer. Hair loss (alopecia) is an expected side effect which may have a significant effect on quality of life. Alopecia is normally temporary but permanent chemotherapy-induced alopecia (pCIA) is increasingly recognised especially following docetaxel chemotherapy. However, the prevalence following docetaxel is not well understood and there is no published literature for paclitaxel chemotherapy. The aim of this study is to investigate the prevalence and patterns of pCIA resulting from both docetaxel and paclitaxel chemotherapy at two tertiary UK cancer centres. METHODS In collaboration between Clatterbridge Cancer Centre and The Christie NHS Foundation Trusts, a retrospective survey was conducted for breast cancer patients who had received taxane chemotherapy in the neoadjuvant and adjuvant settings. Patients who had concluded chemotherapy at least a year previously were contacted by post and invited to participate by completing a questionnaire and returning it to their treatment centre. Data collected included the incidence and pattern of pCIA using the Savin pictorial hair loss scale, and the methods used by patients to manage it. Fisher's exact test was used to compare pCIA between the docetaxel and paclitaxel cohorts. RESULTS 383 patients responded to the survey (a 63.3% overall response rate). These comprised 245 patients receiving docetaxel and 138 patients treated with paclitaxel. pCIA was reported by 23.3% of patients receiving docetaxel and 10.1% paclitaxel (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|